Quest Laboratories Pte Ltd (Quest) and Innovative Diagnostics Pte Ltd (IDPL) were established in 1995 and 1996 respectively. Quest is the amalgamation of five laboratories, namely Heal Laboratory, The Medical Laboratory, Quest Laboratory, Gribbles Pathology, and Doctor’s Lab; while IDPL was formed from the merger of Meditest Switzerland and Innovative Diagnostics.
Pathology Asia Holdings (PAH), as part of TPG Capital Asia – a leading global private investment firm– acquired both IDPL and Quest in September 2018. After a year of planning and restructuring, we started our journey to merge the 2 entities into one and thus forming Innoquest Diagnostics Pte Ltd.
In March 2021, Innoquest Diagnostics Pte Ltd was officially launched and we operate from seven facilities in Singapore. Our main laboratory is installed with the Roche total laboratory automation system with the capability to perform tests for over 10,000 patient episodes a day.
Supported by a deep bench of industry expertise and our groundbreaking technology, Innoquest is proud to serve clinicians, hospitals, medical centres and their patients through the deployment of advanced diagnostic testing methods and technology. Our extensive network of laboratories offer a wide range of in-vitro diagnostic (“IVD”) tests across laboratory medicine to help detect for diseases or conditions and to monitor a person’s health.
In response to the urgent need to boost our nation’s Covid-19 testing capacity for timely detection, we worked alongside the Ministry of Health to build five Covid-19 testing laboratories in Singapore in 2020. To date, we have performed over 2.1 million Covid-19 swab tests and issued over 6 million patient results since April 2020.
Today, as we move forward together as one new entity, we are committed to delivering on our mission, which is “to transform healthcare and improve the human condition”. We invite you to join us in this exciting journey of pursuing science and innovating for life.